News

UK-based biopharmaceutical company Oxford BioMedica has reported that, as part of Sanofi-Aventis’s reprioritization of its product portfolio, Oxford BioMedica has regained worldwide rights to TroVax, its therapeutic cancer

Swiss biopharmaceutical company Basilea Pharmaceutica has received approval from the Dutch Medicines Evaluation Board for Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema

Milestone Scientific, a developer of advanced injection technologies, has granted China National Medicines Corporation, doing business as Sinopharm, exclusive distribution and marketing rights of the STA Single Tooth

Lipoxen, a biopharmaceutical company, and Cambridge Biostability, or CBL, a developer of temperature-stable vaccines and biopharmaceuticals, have achieved positive preclinical results for the delivery of an enhanced influenza

Phase Forward, a provider of integrated data management solutions for clinical trials and drug safety, has reported a net income of $4.08m, or $0.09 per share, for the

Wyeth has reported a net income of $1.198 billion, or $0.89 per diluted share, for the first quarter of 2009, compared to $1.196 billion, or $0.89 per diluted

The complaint alleges that on April 29, 2009, after the market closed, Sequenom announced that the expected launch of its SEQureDxTM Down syndrome test will be delayed because

Outlook 2009 Novo Nordisk still expects sales growth in 2009 at the level of 10% measured in local currencies. This is based on expectations of continued market penetration

Updated 2009 Financial Guidance We are updating our guidance based on our solid first-quarter performance and our Tepnel acquisition, said Herm Rosenman, the Company’s senior vice president of